$2.24
1.36% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
US45674E1091
Symbol
INAB

IN8bio Inc Stock price

$2.24
-0.06 2.61% 1M
-5.91 72.50% 6M
-5.48 70.97% YTD
-14.03 86.23% 1Y
-52.66 95.92% 3Y
-297.76 99.25% 5Y
-297.76 99.25% 10Y
-297.76 99.25% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+0.03 1.36%
ISIN
US45674E1091
Symbol
INAB
Industry

Key metrics

Basic
Market capitalization
$10.0m
Enterprise Value
$-2.7m
Net debt
positive
Cash
$13.2m
Shares outstanding
4.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.7
Financial Health
Equity Ratio
69.1%
Return on Equity
-210.2%
ROCE
-138.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-21.0m | $-15.3m
EBIT
$-24.2m | $-20.7m
Net Income
$-23.9m | $-27.9m
Free Cash Flow
$-17.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
30.8% | 43.2%
EBIT
24.6% | 30.0%
Net Income
25.3% | 8.4%
Free Cash Flow
30.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-5.8
FCF per Share
$-4.2
Short interest
3.7%
Employees
18
Rev per Employee
$0.0
Show more

Is IN8bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

IN8bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a IN8bio Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a IN8bio Inc forecast:

Buy
90%
Hold
10%

Financial data from IN8bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
16% 16%
-
- Research and Development Expense 12 12
33% 33%
-
-21 -21
31% 31%
-
- Depreciation and Amortization 3.24 3.24
80% 80%
-
EBIT (Operating Income) EBIT -24 -24
25% 25%
-
Net Profit -24 -24
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about IN8bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IN8bio Inc Stock News

Neutral
The Motley Fool
14 days ago
IN8bio (INAB) Q2 Loss Narrows 77%
Neutral
GlobeNewsWire
14 days ago
Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years. Received the Host Region USA East Abstract Award at ISCT 2025 for IN8bio's DeltEx™ manufacturing platform.
Neutral
GlobeNewsWire
2 months ago
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recently reached a significant clinical milestone. The patient, with a grade 4, IDH-mutant glioma, has been...
More IN8bio Inc News

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Head office United States
CEO William Ho
Employees 18
Founded 2016
Website www.in8bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today